TIDMEKF

RNS Number : 2342J

EKF Diagnostics Holdings PLC

02 April 2015

EKF Diagnostics Holdings plc

("EKF", the "Company")

Shareholder update

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that the Board of Directors have initiated a strategic review.

An independent committee of the Non-Executive Directors will lead the strategic review, chaired by Dr Kevin Wilson and consisting of Adam Reynolds, David Toohey and Doris Ann Williams.

The independent committee are committed to completing their review as soon as practicable.

Enquiries:

 
EKF Diagnostics Holdings plc                                       Tel: 029 2071 0570 
David Evans, Executive Chairman                                    Mob: 07740 084 452 
Dr Kevin Wilson, Chair of the independent                          Mob: 07796 697 594 
 committee 
 
Panmure Gordon (UK) Limited 
Robert Naylor (Corporate Finance)                                  Tel: 020 7886 2714 
Paul Fincham (Corporate Finance)                                   Tel: 020 7886 2713 
Maisie Atkinson (Corporate                                         Tel: 020 7886 2905 
 Broking) 
Michael Seabrook (Sales)                                           Tel: 020 7886 2704 
 
Walbrook PR Limited                          Tel: 020 7933 8780 or ekf@walbrookpr.com 
Paul McManus                                                       Mob: 07980 541 893 
Lianne Cawthorne                                                   Mob: 07584 391 303

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for EUR14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUUCCUPAGAG

Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Ekf Diagnostics Charts.
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Ekf Diagnostics Charts.